These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 29220294)

  • 1. Clinical and Molecular Spectrum of Liposarcoma.
    Lee ATJ; Thway K; Huang PH; Jones RL
    J Clin Oncol; 2018 Jan; 36(2):151-159. PubMed ID: 29220294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposarcomas in young patients: a study of 82 cases occurring in patients younger than 22 years of age.
    Alaggio R; Coffin CM; Weiss SW; Bridge JA; Issakov J; Oliveira AM; Folpe AL
    Am J Surg Pathol; 2009 May; 33(5):645-58. PubMed ID: 19194281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview on liposarcoma subtypes: Genetic alterations and recent advances in therapeutic strategies.
    M S A; K C; Bhargavan RV; Somanathan T; Subhadradevi L
    J Mol Histol; 2024 Jun; 55(3):227-240. PubMed ID: 38696048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dedifferentiated liposarcoma with "homologous" lipoblastic (pleomorphic liposarcoma-like) differentiation: clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria.
    Mariño-Enríquez A; Fletcher CD; Dal Cin P; Hornick JL
    Am J Surg Pathol; 2010 Aug; 34(8):1122-31. PubMed ID: 20588177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What's new in adipocytic neoplasia?
    Creytens D
    Virchows Arch; 2020 Jan; 476(1):29-39. PubMed ID: 31501988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on liposarcoma: a review for cytopathologists.
    Dodd LG
    Diagn Cytopathol; 2012 Dec; 40(12):1122-31. PubMed ID: 21932353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposarcoma: new entities and evolving concepts.
    Dei Tos AP
    Ann Diagn Pathol; 2000 Aug; 4(4):252-66. PubMed ID: 10982304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposarcomas of the mediastinum and thorax: a clinicopathologic and molecular cytogenetic study of 24 cases, emphasizing unusual and diverse histologic features.
    Boland JM; Colby TV; Folpe AL
    Am J Surg Pathol; 2012 Sep; 36(9):1395-403. PubMed ID: 22895273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct chromosomal imbalances in pleomorphic and in high-grade dedifferentiated liposarcomas.
    Rieker RJ; Joos S; Bartsch C; Willeke F; Schwarzbach M; Otaño-Joos M; Ohl S; Högel J; Lehnert T; Lichter P; Otto HF; Mechtersheimer G
    Int J Cancer; 2002 May; 99(1):68-73. PubMed ID: 11948494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dedifferentiated Liposarcoma: Updates on Morphology, Genetics, and Therapeutic Strategies.
    Thway K; Jones RL; Noujaim J; Zaidi S; Miah AB; Fisher C
    Adv Anat Pathol; 2016 Jan; 23(1):30-40. PubMed ID: 26645460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective elimination of amplified CDK4 sequences correlates with spontaneous adipocytic differentiation in liposarcoma.
    Hélias-Rodzewicz Z; Pédeutour F; Coindre JM; Terrier P; Aurias A
    Genes Chromosomes Cancer; 2009 Nov; 48(11):943-52. PubMed ID: 19626636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposarcoma initiated by FUS/TLS-CHOP: the FUS/TLS domain plays a critical role in the pathogenesis of liposarcoma.
    Pérez-Losada J; Sánchez-Martín M; Rodríguez-García MA; Pérez-Mancera PA; Pintado B; Flores T; Battaner E; Sánchez-Garćia I
    Oncogene; 2000 Dec; 19(52):6015-22. PubMed ID: 11146553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme.
    Snyder EL; Sandstrom DJ; Law K; Fiore C; Sicinska E; Brito J; Bailey D; Fletcher JA; Loda M; Rodig SJ; Dal Cin P; Fletcher CD
    J Pathol; 2009 Jul; 218(3):292-300. PubMed ID: 19449367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing Liposarcomas: Cutting Through the Fat.
    Manji GA; Schwartz GK
    J Oncol Pract; 2016 Mar; 12(3):221-7. PubMed ID: 26962163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogene mutation profiling reveals poor prognosis associated with FGFR1/3 mutation in liposarcoma.
    Li C; Shen Y; Ren Y; Liu W; Li M; Liang W; Liu C; Li F
    Hum Pathol; 2016 Sep; 55():143-50. PubMed ID: 27237367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gains of 13q are correlated with a poor prognosis in liposarcoma.
    Schmidt H; Bartel F; Kappler M; Würl P; Lange H; Bache M; Holzhausen HJ; Taubert H
    Mod Pathol; 2005 May; 18(5):638-44. PubMed ID: 15540119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of retroperitoneal liposarcoma genomics.
    Tyler R; Wanigasooriya K; Taniere P; Almond M; Ford S; Desai A; Beggs A
    Cancer Treat Rev; 2020 Jun; 86():102013. PubMed ID: 32278233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [From cytogenetics to cytogenomics of adipose tissue tumors: 2. Malignant adipose tissue tumors].
    Pedeutour F; Maire G; Sirvent N;
    Bull Cancer; 2004 Apr; 91(4):317-23. PubMed ID: 15242313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant calreticulin expression is involved in the dedifferentiation of dedifferentiated liposarcoma.
    Hisaoka M; Matsuyama A; Nakamoto M
    Am J Pathol; 2012 May; 180(5):2076-83. PubMed ID: 22429966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Well-differentiated liposarcoma and dedifferentiated liposarcoma: An updated review.
    Thway K
    Semin Diagn Pathol; 2019 Mar; 36(2):112-121. PubMed ID: 30852045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.